FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1190-1196 October 14, 1999 Number 16 Next

Abstract PDF Editorial by Fanaroff, A. A. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Antenatal glucocorticoid therapy decreases the incidence of several complications among very premature infants. However, its effect on the occurrence of cystic periventricular leukomalacia, a major cause of cerebral palsy, remains unknown.

Methods We retrospectively analyzed a cohort of 883 live-born infants, with gestational ages ranging from 24 to 31 weeks, who were born between January 1993 and December 1996 at three perinatal centers in the Paris area. The mothers of 361 infants had received betamethasone before delivery, the mothers of 165 infants had received dexamethasone before delivery, and the mothers of 357 infants did not receive glucocorticoids. We compared the rates of cystic periventricular leukomalacia among the three groups of infants in bivariate and multivariate analyses after adjustment for confounding factors.

Results The rate of cystic periventricular leukomalacia was 4.4 percent among the infants whose mothers had received betamethasone, 11.0 percent among the infants whose mothers had received dexamethasone, and 8.4 percent among the infants whose mothers had not received a glucocorticoid. After adjustment for gestational age, the mode of delivery, and the presence or absence of chorioamnionitis, prolonged interval between the rupture of membranes and delivery (>24 hours), preeclampsia, and the use of tocolytic drugs, antenatal exposure to betamethasone was associated with a lower risk of cystic periventricular leukomalacia than was either the absence of glucocorticoid therapy (adjusted odds ratio, 0.5; 95 percent confidence interval, 0.2 to 0.9) or exposure to dexamethasone (adjusted odds ratio, 0.3; 95 percent confidence interval, 0.1 to 0.7). The adjusted odds ratio for the group of infants whose mothers had received dexamethasone as compared with the group of infants whose mothers had not received a glucocorticoid was 1.5 (95 percent confidence interval, 0.8 to 2.9).

Conclusions Antenatal exposure to betamethasone but not dexamethasone is associated with a decreased risk of cystic periventricular leukomalacia among very premature infants.

A National Institutes of Health consensus conference on the effect of glucocorticoids on fetal maturation identified several areas that need to be studied, including the effects of antenatal glucocorticoid administration on perinatal hypoxic–ischemic brain injury.² Indeed, in contrast to the case of intraventricular hemorrhage, little is known about the relation between antenatal glucocorticoid administration and the incidence of cystic periventricular leukomalacia, the most frequent cause of cerebral palsy in children who are born prematurely. Therefore, we assessed the effect of various obstetrical variables, including antenatal exposure to betamethasone and dexamethasone, on the incidence of cystic periventricular leukomalacia in very premature infants.

Methods

This retrospective study was carried out in three perinatal centers of the Assistance Publique–Hôpitaux de Paris organization. We studied all 883 infants with gestational ages ranging from 24 to 31 weeks who were born in these centers and who were subsequently admitted to the neonatal intensive care unit between January 1993 and December 1996. We reviewed the records of all the mothers to determine the causes of preterm delivery, the dates of administration and number of courses of glucocorticoid, the glucocorticoid regimen used, any use of tocolytic and antibiotic therapy, and the mode of delivery. We also reviewed the records of the infants.

Glucocorticoid Therapy

At the time of the study, the recommended antenatal glucocorticoid regimen consisted of the administration to the women of either two 12-mg doses of betamethasone (Célestène or Célestène chronodose, Roche, Paris) given intramuscularly 24 hours apart or four 6-mg doses of dexamethasone (Soludecadron, Merck, Paris) given intramuscularly 12 hours apart. Both glucocorticoids were used in the three centers during the study period. If the women had not delivered and were still at risk for preterm delivery, additional courses of the same regimen were administered every 7 to 10 days.

Antenatal Events

Gestational age was based on the date of the last menstrual period and on ultrasonographic findings during the first trimester of pregnancy. The main causes of preterm delivery were chorioamnionitis, rupture of amniotic membranes more than 24 hours before delivery, vaginal bleeding (placenta previa or placental abruption), intrauterine growth retardation, and preeclampsia. Chorioamnionitis was defined by the presence of preterm labor in association with at least two of the following prepartum or postpartum criteria: maternal temperature of more than 38°C on at least two occasions, maternal serum C-reactive protein concentration of more than 20 mg per liter (normal, <10), positive bacterial culture of amniotic fluid obtained by amniocentesis, and documented neonatal sepsis. Intrauterine growth retardation was diagnosed by ultrasonography; all cases were confirmed after delivery (on the basis of a birth weight below the 10th percentile).⁷ Preeclampsia was defined on the basis of the finding of urinary protein excretion of more than 300 mg per 24 hours and a blood pressure of more than 140/90 mm Hg on two occasions.

In addition to antenatal glucocorticoid therapy, maternal treatments considered in the study were the use of intravenous tocolysis with albuterol (Glaxo, Boulogne, France), intravenous antibiotics, and antihypertensive drugs. Magnesium sulfate was not used as a tocolytic agent or for the treatment of preeclampsia during the study period.

Short-Term Neonatal Outcomes

All outcomes, including death, were recorded until the infants were discharged from the hospital. Respiratory distress syndrome was diagnosed when at least two of the following were present during the first 48 hours of life: respiratory failure requiring either mechanical ventilation with supplemental oxygen for at least 48 hours or the administration of exogenous surfactant, typical findings on chest x-ray film (reticulogranular pattern in the lungs with air bronchograms), or biologic evidence of lung immaturity on assay of tracheal aspirates (TDx Fetal-Lung-Maturity Assay II, Abbott Laboratories, North Chicago, Ill.). Bronchopulmonary dysplasia was defined by the need for supplemental oxygen at 28 days of life; its incidence was calculated in survivors at the same age. Necrotizing enterocolitis was diagnosed with the use of a standard combination of clinical signs and radiographic findings.⁸

Cranial ultrasonography was usually performed twice within the first week of life and weekly thereafter until 36 weeks of gestational age, and all three centers used similar techniques. Electroencephalography was performed at least once a week up to an average of 34 weeks of gestational age.⁹ The infants were assessed for severe intraventricular hemorrhage (grades 3 and 4 according to the classification of Papile et al.¹⁰) and cystic periventricular leukomalacia. The presence of the latter was suggested by a finding of rolandic sharp waves on electroencephalography⁹ and confirmed by a finding of bilateral hyperechoic lesions on cranial ultrasonography soon after birth, which evolved into localized or extensive echolucent areas within the brain parenchyma.¹¹

Ophthalmoscopy was performed 4 weeks after birth and every 2 weeks thereafter until 36 to 40 weeks of gestational age. Only the most severe stages of retinopathy of prematurity (stages 3 to 5) were recorded.¹²

Statistical Analysis

Antenatal events and neonatal outcome were compared by bivariate analysis according to whether or not the mother had received either betamethasone or dexamethasone. The rates of cystic periventricular leukomalacia in each of the three groups (untreated, exposed to betamethasone, and exposed to dexamethasone) were then analyzed after stratification according to maternal and neonatal variables. Finally, the relations between antenatal glucocorticoid treatment and the occurrence of cystic periventricular leukomalacia were estimated by two separate multiple logistic-regression models.¹³ In the first model, each of the two treated groups was compared with the untreated group; in the second model, the betamethasone group was compared with the dexamethasone group. Pearson's chi-square test was used to analyze categorical data. All P values were based on two-sided tests. Bivariate and multivariate analyses were performed with SAS statistical software (SAS Institute, Cary, N.C.) and BMDP software (BMDP Statistical Software, Los Angeles), respectively.

Results

Characteristics of the Infants and Their Mothers

The study cohort consisted of 883 infants who were born between 24 and 31 weeks of gestation to 718 women; 361 infants (41 percent) were exposed to betamethasone, 165 (19 percent) to dexamethasone, and 357 (40 percent) to neither glucocorticoid. The maternal characteristics are shown in Table 1, and neonatal characteristics in Table 2. There were significant differences in the distribution of gestational age among the three groups, with fewer of the most immature infants in the treated groups. As compared with the infants whose mothers had not received glucocorticoids, the infants whose mothers had received either betamethasone or dexamethasone were less likely to require exogenous surfactant and had lower rates of respiratory distress syndrome, bronchopulmonary dysplasia (indicated by the need for supplemental oxygen at 28 days of life), and grade 3 or 4 intraventricular hemorrhage (Table 2).

View this table: [in this window] [in a new window]   Table 1. Maternal Characteristics According to the Antenatal Use of Glucocorticoids.

 

View this table: [in this window] [in a new window]   Table 2. Characteristics of the Neonates According to the Antenatal Use of Glucocorticoids.

 
Infants with intrauterine growth retardation were more likely to have been exposed to dexamethasone than to betamethasone, whereas infants born after a prolonged interval between the rupture of amniotic membranes and delivery were more likely to have been exposed to betamethasone (Table 1 and Table 2). There was no significant difference between the two treated groups in the number of full courses of glucocorticoid given antenatally. The interval between the first intramuscular injection of the last course of glucocorticoid and delivery was not significantly different in the two treated groups. The frequency of respiratory distress syndrome, bronchopulmonary dysplasia, grade 3 or 4 intraventricular hemorrhage, necrotizing enterocolitis, and stage 3, 4, or 5 retinopathy of prematurity was similar in the two treated groups (Table 2). However, as compared with either the infants with no exposure to glucocorticoids or the infants whose mothers received dexamethasone, the infants whose mothers received betamethasone were less likely to have cystic periventricular leukomalacia. As compared with the infants with no exposure to glucocorticoids, the infants whose mothers had received betamethasone had a significantly lower overall rate of death (Table 2).

The rates of use of dexamethasone or betamethasone differed in the three centers (Table 3). The rate of cystic periventricular leukomalacia was the lowest in the center in which betamethasone was given more often. Moreover, at each center, the rate of cystic periventricular leukomalacia was lowest in the group of infants whose mothers had received betamethasone (Table 3).

View this table: [in this window] [in a new window]   Table 3. Gestational Age, Use of Antenatal Glucocorticoid Treatment, and Incidence of Cystic Periventricular Leukomalacia, According to Center.

 
Risk Factors for Cystic Periventricular Leukomalacia

The overall incidence of cystic periventricular leukomalacia ranged from 12.9 percent among infants whose gestational age was 24 to 26 weeks to 4.2 percent among infants whose gestational age was 30 to 31 weeks (Table 4). Chorioamnionitis, a prolonged interval between the rupture of membranes and delivery, the use of tocolytic drugs, and vaginal delivery were the peripartum events associated with a higher rate of cystic periventricular leukomalacia. In contrast, cystic periventricular leukomalacia was rare among infants whose mothers had preeclampsia.

View this table: [in this window] [in a new window]   Table 4. Incidence of Cystic Periventricular Leukomalacia According to Selected Maternal and Neonatal Characteristics.

 
Effect of Antenatal Glucocorticoid Treatment on the Risk of Cystic Periventricular Leukomalacia

For any degree of immaturity and in almost all subgroups, there was a trend toward a lower frequency of cystic periventricular leukomalacia in the betamethasone group than in either the untreated group or the dexamethasone-exposed group (Table 5). The relation between the type of glucocorticoid given and the risk of cystic periventricular leukomalacia was estimated in two multiple logistic-regression models, after adjustment for the covariates that were significantly associated with that outcome: gestational age, the mode of delivery, and the presence or absence of chorioamnionitis, prolonged interval between rupture of membranes and delivery, preeclampsia, and use of tocolytic drugs. As compared with no treatment (Table 6), antenatal administration of betamethasone was associated with a lower risk of cystic periventricular leukomalacia (adjusted odds ratio, 0.5; 95 percent confidence interval, 0.2 to 0.9; P=0.03), whereas dexamethasone was associated with a higher risk, but not a significantly higher risk (adjusted odds ratio, 1.5; 95 percent confidence interval, 0.8 to 2.9; P=0.20).

View this table: [in this window] [in a new window]   Table 5. Incidence of Cystic Periventricular Leukomalacia According to the Antenatal Use of Glucocorticoids.

 

View this table: [in this window] [in a new window]   Table 6. Results of Multiple Logistic-Regression Analysis of the Risk of Cystic Periventricular Leukomalacia.

 
In a separate multiple logistic-regression model, the administration of betamethasone was associated with a lower risk of cystic periventricular leukomalacia than was the administration of dexamethasone (unadjusted odds ratio, 0.4; 95 percent confidence interval, 0.2 to 0.8; adjusted odds ratio, 0.3; 95 percent confidence interval, 0.1 to 0.7; P=0.003). Although the proportion of infants who were exposed to either betamethasone or dexamethasone varied according to the center and during the study period, the associations were not affected by the addition of these two variables to the models. The results were similar after the exclusion of infants who had died within the first seven days after birth.

Among infants from multiple pregnancies, there was no evidence of concordance for disease outcome with respect to the risk of cystic periventricular leukomalacia. A separate analysis was nevertheless performed for singleton infants. Among singleton infants, the adjusted odds ratio in the betamethasone-exposed group as compared with the unexposed group was 0.6 (95 percent confidence interval, 0.3 to 1.4) and the adjusted odds ratio for the comparison of the betamethasone-exposed group with the dexamethasone-exposed group was 0.3 (95 percent confidence interval, 0.1 to 0.8).

Discussion

Several observational studies have identified a relation between chorioamnionitis, cystic periventricular leukomalacia, and cerebral palsy.^14,15,16,17 In contrast, the infants of mothers who had preeclampsia have a low risk of either cystic periventricular leukomalacia or cerebral palsy.^15,16 Antenatal glucocorticoid therapy with betamethasone or dexamethasone reduces the risk of intracranial hemorrhage in neonates.¹ Our results suggest that exposure to betamethasone but not dexamethasone is associated with a decreased risk of cystic periventricular leukomalacia.

Several limitations of our study must be underlined. First of all, it was observational. Despite the repeated use of cranial ultrasonography and electroencephalography at the three centers, a few cases of cystic periventricular leukomalacia may not have been detected. It is likely, however, that any undetected cases were evenly distributed among the three groups. It is also impossible to control completely for indication bias in such an observational study; Table 1 shows that the prevalence of antenatal risk factors for cystic periventricular leukomalacia varied according to the antenatal glucocorticoid treatment given. However, chorioamnionitis and a prolonged interval between the rupture of membranes and delivery — two high-risk factors for cystic periventricular leukomalacia — were more frequent among infants whose mothers had received betamethasone than among infants whose mothers had received dexamethasone. Moreover, at each center, the infants whose mothers had received betamethasone had the lowest rate of cystic periventricular leukomalacia. Finally, the consistent decrease in the risk of cystic periventricular leukomalacia that was associated with antenatal exposure to betamethasone, which was apparent in both the stratified analysis and the multiple logistic-regression analyses, suggests that this beneficial effect is due to the treatment and not only to the characteristics of the women who received it.

Whether the subtle structural difference in the configuration of the methyl group on position 16 — the only difference between betamethasone and dexamethasone — accounts for the neuroprotective effects of betamethasone remains speculative. Alternatively, the presence of sulfiting agents in the dexamethasone preparation (the preparation available in France contains 0.155 mg of sulfite per milligram of dexamethasone) may account for its lower efficacy. Sulfite acts in vitro as a neurotoxic agent, especially in combination with peroxynitrite.^18,19

Betamethasone has a more pronounced effect than dexamethasone on the variation in fetal heart rate, which may confound the assessment of the well-being of fetuses with growth retardation.^4,5 Nonetheless, in addition to the unexpected protective effect of betamethasone in this study, there is other evidence to suggest that betamethasone may be preferable to dexamethasone. First, the offspring of pregnant mice given betamethasone performed neurobehavioral-development tasks better than the offspring of pregnant mice given dexamethasone.²⁰ Second, meta-analyses of randomized trials have shown that although both glucocorticoids reduce the frequency of the respiratory distress syndrome, only betamethasone reduces neonatal mortality.³ Finally, both drugs have similar beneficial effects on all the other major adverse outcomes of severe prematurity, and treatment with betamethasone requires fewer intramuscular injections. For all these reasons, betamethasone may prove to be the better choice for pregnant women at risk for preterm delivery.

We are indebted to the staff members of the departments of obstetrics and pediatrics of the participating hospitals; to Drs. R. Lenclen and Y. Ville at the Hospital of Poissy; and to Drs. P. Blanchard (Sherbrooke University, Sherbrooke, Que., Canada), M.V. Sénat (Antoine Béclère Hospital, Clamart, France), P. Truffert (Jeanne de Flandre Hospital, Lille, France), and V. Zupan (Antoine Béclère Hospital, Clamart, France) for their advice during the preparation of this article.

Source Information

From the Services de Réanimation Néonatale et Gynécologie–Obstétrique, University Hospital Antoine Béclère, Clamart (O.B., L.F.-L., F.A., M.D., T.L.-M.); the Unité de Recherches Epidémiologiques sur la Santé des Femmes et des Enfants, INSERM, Unité 149, Villejuif (L.F.-L., M.K.); the Services de Réanimation Néonatale et Gynécologie–Obstétrique, University Hospital Cochin Port Royal, Paris (P.-H.J., E.P.); and the Services de Réanimation Néonatale et Gynécologie–Obstétrique, University Hospital Saint Vincent de Paul, Paris (C.H., J.L.) — all in France.

Address reprint requests to Dr. Lacaze-Masmonteil at Réanimation et Pédiatrie Néonatales, Hôpital Antoine Béclère, Assistance Publique–Hôpitaux de Paris, 157, rue de la Porte-de-Trivaux, 92141 Clamart, France.

References

1. Crowley P. Antenatal corticosteroid therapy: a meta-analysis of the randomized trials, 1972 to 1994. Am J Obstet Gynecol 1995;173:322-335. [CrossRef][Medline]
2. NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. Effect of corticosteroids for fetal maturation on perinatal outcomes. JAMA 1995;273:413-418. [Free Full Text]
3. Ballard PL, Ballard RA. Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. Am J Obstet Gynecol 1995;173:254-262. [CrossRef][Medline]
4. Mulder EJH, Derks JB, Visser GHA. Antenatal corticosteroid therapy and fetal behaviour: a randomised study of the effects of betamethasone and dexamethasone. Br J Obstet Gynaecol 1997;104:1239-1247. [Medline]
5. Senat MV, Minoui S, Multon O, Fernandez H, Frydman R, Ville Y. Effect of dexamethasone and betamethasone on fetal heart rate variability in preterm labour: a randomised study. Br J Obstet Gynaecol 1998;105:749-755. [Medline]
6. Magee LA, Dawes GS, Moulden M, Redman CW. A randomised controlled comparison of betamethasone and dexamethasone: effects on the antenatal fetal heart rate. Br J Obstet Gynaecol 1997;104:1233-1238. [Medline]
7. Leroy B, Lefort F. A propos du poids et de la taille des nouveau-nés à la naissance. Rev Fr Gynecol Obstet 1971;66:391-396. [Medline]
8. Kliegman RM, Fanaroff AA. Necrotizing enterocolitis. N Engl J Med 1984;310:1093-1103. [Medline]
9. Baud O, d'Allest AM, Lacaze-Masmonteil T, et al. The early diagnosis of periventricular leukomalacia in premature infants with positive rolandic sharp waves on serial electroencephalography. J Pediatr 1998;132:813-817. [CrossRef][Medline]
10. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978;92:529-534. [CrossRef][Medline]
11. de Vries LS. Neurological assessment of the preterm infant. Acta Paediatr 1996;85:765-771. [Medline]
12. The Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch Ophthalmol 1984;102:1130-1134. [Free Full Text]
13. Hosmer DW Jr, Lemeshow S. Applied logistic regression. New York: Wiley, 1989:307.
14. Nelson KB, Ellenberg JH. Predictors of low and very low birth weight and the relation of these to cerebral palsy. JAMA 1985;254:1473-1479. [Free Full Text]
15. Zupan V, Gonzalez P, Lacaze-Masmonteil T, et al. Periventricular leukomalacia: risk factors revisited. Dev Med Child Neurol 1996;38:1061-1067. [Medline]
16. Murphy DJ, Sellers S, MacKenzie IZ, Yudkin PL, Johnson AM. Case-control study of antenatal and intrapartum risk factors for cerebral palsy in very preterm singleton babies. Lancet 1995;346:1449-1454. [CrossRef][Medline]
17. Spinillo A, Capuzzo E, Stronati M, Ometto A, De Santolo A, Acciano S. Obstetric risk factors for periventricular leukomalacia among preterm infants. Br J Obstet Gynaecol 1998;105:865-871. [Medline]
18. Reist M, Marshall KA, Jenner P, Halliwell B. Toxic effects of sulfite in combination with peroxynitrite on neuronal cells. J Neurochem 1998;71:2431-2438. [Medline]
19. Leist M, Fava E, Montecucco C, Nicotera P. Peroxynitrite and nitric oxide donors induce neuronal apoptosis by eliciting autocrine excitotoxicity. Eur J Neurosci 1997;9:1488-1498. [CrossRef][Medline]
20. Rayburn WF, Christensen HD, Gonzalez CL. A placebo-controlled comparison between betamethasone and dexamethasone for fetal maturation: differences in neurobehavioral development of mice offspring. Am J Obstet Gynecol 1997;176:842-851. [CrossRef][Medline]

Abstract PDF Editorial by Fanaroff, A. A. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

This article has been cited by other articles:

• McElrath, T. F., Allred, E. N., Boggess, K. A., Kuban, K., O'Shea, T. M., Paneth, N., Alan Leviton for the ELGAN Study Investigators, (2009). Maternal Antenatal Complications and the Risk of Neonatal Cerebral White Matter Damage and Later Cerebral Palsy in Children Born at an Extremely Low Gestational Age. Am J Epidemiol 170: 819-828 [Abstract] [Full Text]  
• Warren, J. B., Anderson, J. M. (2009). Core Concepts: Respiratory Distress Syndrome. NeoReviews 10: e351-e361 [Abstract] [Full Text]  
• Amin, S. B., Guillet, R. (2007). Auditory Neural Maturation After Exposure to Multiple Courses of Antenatal Betamethasone in Premature Infants as Evaluated by Auditory Brainstem Response. Pediatrics 119: 502-508 [Abstract] [Full Text]  
• Chatterjee, J., Gullam, J., Vatish, M., Thornton, S. (2007). The management of preterm labour. Arch. Dis. Child. Fetal Neonatal Ed. 92: F88-F93 [Full Text]  
• Parke, A (2006). Drug exposure, pregnancy outcome and fetal and childhood development occurring in the offspring of mothers with systemic lupus erythematosus and other chronic autoimmune diseases. Lupus 15: 808-813 [Abstract]  
• Shankaran, S., Langer, J. C., Kazzi, S. N., Laptook, A. R., Walsh, M., for the National Institute of Child Health and Hum, (2006). Cumulative Index of Exposure to Hypocarbia and Hyperoxia as Risk Factors for Periventricular Leukomalacia in Low Birth Weight Infants. Pediatrics 118: 1654-1659 [Abstract] [Full Text]  
• Airo, P, Scarsi, M, Brucato, A, Benicchi, T, Malacarne, F, Cavazzana, I, Danieli, E, LiDestri, M, Motta, M, Caimi, L, Tincani, A, Imberti, L (2006). Characterization of T-cell population in children with prolonged fetal exposure to dexamethasone for anti-Ro/SS-A antibodies associated congenital heart block. Lupus 15: 553-561 [Abstract]  
• Jobe, A. H. (2006). Prenatal Corticosteroids: A Neonatologist's Perspective. NeoReviews 7: e259-e267 [Full Text]  
• Lee, B. H., Stoll, B. J., McDonald, S. A., Higgins, R. D., for the National Institute of Child Health and Hum, (2006). Adverse Neonatal Outcomes Associated With Antenatal Dexamethasone Versus Antenatal Betamethasone. Pediatrics 117: 1503-1510 [Abstract] [Full Text]  
• Tincani, A, Bompane, D, Danieli, E, Doria, A (2006). Pregnancy, lupus and antiphospholipid syndrome (Hughes syndrome). Lupus 15: 156-160 [Abstract]  
• Walsh, M. C., Szefler, S., Davis, J., Allen, M., Van Marter, L., Abman, S., Blackmon, L., Jobe, A. (2006). Summary proceedings from the bronchopulmonary dysplasia group.. Pediatrics 117: S52-S56 [Abstract] [Full Text]  
• Vural, M, Yilmaz, I, Oztunc, F, Ilikkan, B, Erginoz, E, Perk, Y (2006). Cardiac effects of a single course of antenatal betamethasone in preterm infants. Arch. Dis. Child. Fetal Neonatal Ed. 91: F118-F122 [Abstract] [Full Text]  
• Costedoat-Chalumeau, N, Georgin-Lavialle, S, Amoura, Z, Piette, J-C (2005). Anti-SSA/Ro and anti-SSB/La antibody-mediated congenital heart block. Lupus 14: 660-664 [Abstract]  
• Wood, N S, Costeloe, K, Gibson, A T, Hennessy, E M, Marlow, N, Wilkinson, A R, for the EPICure Study Group, (2005). The EPICure study: associations and antecedents of neurological and developmental disability at 30 months of age following extremely preterm birth. Arch. Dis. Child. Fetal Neonatal Ed. 90: F134-F140 [Abstract] [Full Text]  
• Foix-L'Helias, L, Baud, O, Lenclen, R, Kaminski, M, Lacaze-Masmonteil, T (2005). Benefit of antenatal glucocorticoids according to the cause of very premature birth. Arch. Dis. Child. Fetal Neonatal Ed. 90: F46-F48 [Abstract] [Full Text]  
• Jobe, A. H. (2004). Postnatal Corticosteroids for Preterm Infants -- Do What We Say, Not What We Do. NEJM 350: 1349-1351 [Full Text]  
• Baud, O (2004). Postnatal steroid treatment and brain development. Arch. Dis. Child. Fetal Neonatal Ed. 89: F96-F100 [Abstract] [Full Text]  
• Costedoat-Chalumeau, N, Amoura, Z, Le Thi Hong, D, Wechsler, B, Vauthier, D, Ghillani, P, Papo, T, Fain, O, Musset, L, Piette, J-C (2003). Questions about dexamethasone use for the prevention of anti-SSA related congenital heart block. Ann Rheum Dis 62: 1010-1012 [Abstract] [Full Text]  
• Carteaux, P., Cohen, H., Check, J., George, J., McKinley, P., Lewis, W., Hegwood, P., Whitfield, J. M., McLendon, D., Okuno-Jones, S., Klein, S., Moehring, J., McConnell, C. (2003). Evaluation and Development of Potentially Better Practices for the Prevention of Brain Hemorrhage and Ischemic Brain Injury in Very Low Birth Weight Infants. Pediatrics 111: e489-496 [Abstract] [Full Text]  
• LeFlore, J. L., Salhab, W. A., Broyles, R. S., Engle, W. D. (2002). Association of Antenatal and Postnatal Dexamethasone Exposure With Outcomes in Extremely Low Birth Weight Neonates. Pediatrics 110: 275-279 [Abstract] [Full Text]  
• Avent, M., Coile, D., Mathai, L. (2001). Neonatal Chronic Lung Disease. Journal of Pharmacy Practice 14: 181-206 [Abstract]  
• Kadhim, H., Tabarki, B., Verellen, G., De Prez, C., Rona, A.-M., Sebire, G. (2001). Inflammatory cytokines in the pathogenesis of periventricular leukomalacia. Neurology 56: 1278-1284 [Abstract] [Full Text]  
• Thébaud, B., Lacaze-Masmonteil, T., Watterberg, K. (2001). Postnatal Glucocorticoids in Very Preterm Infants: "The Good, the Bad, and the Ugly"?. Pediatrics 107: 413-415 [Full Text]  
• Shinwell, E S, Karplus, M, Reich, D, Weintraub, Z, Blazer, S, Bader, D, Yurman, S, Dolfin, T, Kogan, A, Dollberg, S, Arbel, E, Goldberg, M, Gur, I, Naor, N, Sirota, L, Mogilner, S, Zaritsky, A, Barak, M, Gottfried, E (2000). Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch. Dis. Child. Fetal Neonatal Ed. 83: 177F-181 [Abstract] [Full Text]  
• Wu, Y. W., Colford, J. M. Jr (2000). Chorioamnionitis as a Risk Factor for Cerebral Palsy: A Meta-analysis. JAMA 284: 1417-1424 [Abstract] [Full Text]  
• Whitelaw, A., Thoresen, M. (2000). Antenatal steroids and the developing brain. Arch. Dis. Child. Fetal Neonatal Ed. 83: 154F-157 [Abstract] [Full Text]  
• Merrill, J. D., Ballard, R. A. (2000). Clinical Use of Antenatal Corticosteroids: Benefits and Risks. NeoReviews 1: e91-98 [Full Text]  
• Fanaroff, A. A., Hack, M. (1999). Periventricular Leukomalacia -- Prospects for Prevention. NEJM 341: 1229-1231 [Full Text]